Evidence map›Paper›PMID 35377426›Full record

ArticleJAMA network open2022

Association of Genetic Variants Linked to Late-Onset Alzheimer Disease With Cognitive Test Performance by Midlife.

Scott C Zimmerman, Willa D Brenowitz, Camilla Calmasini, Sarah F Ackley, Rebecca E Graff, Stephen B Asiimwe, Adam M Staffaroni, Thomas J Hoffmann, M Maria Glymour

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The role of polygenic risk in Alzheimer's disease prediction for African Americans.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Cognitive trajectories diverge by genetic risk in a preclinical longitudinal cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Article
  17. Apolipoprotein E moderates the association between Non-medRxiv : the preprint server for health sciences · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Scott C ZimmermanDepartment of Epidemiology and Biostatistics, University of California, San Francisco.
Willa D BrenowitzDepartment of Epidemiology and Biostatistics, University of California, San Francisco.
Camilla CalmasiniDepartment of Epidemiology and Biostatistics, University of California, San Francisco.
Sarah F AckleyDepartment of Epidemiology and Biostatistics, University of California, San Francisco.
Rebecca E GraffDepartment of Epidemiology and Biostatistics, University of California, San Francisco.
Stephen B AsiimweDepartment of Epidemiology and Biostatistics, University of California, San Francisco.
Adam M StaffaroniWeill Institute for Neurosciences, Department of Neurology, Memory and Aging Center, University of California, San Francisco.
Thomas J HoffmannDepartment of Epidemiology and Biostatistics, University of California, San Francisco.
M Maria GlymourDepartment of Epidemiology and Biostatistics, University of California, San Francisco.
University of California, San Francisco · USCenter for Neurosciences · US

Funding

Closing the gap between observational research and randomized trials for prevention of Alzheimer's Disease and dementiaR01AG057869 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRAFF, REBECCA ELIZABETH, POWER, MELINDA C · 2018 to 2022
$3.9M
Older Persons &Drugs: race, gender, and age effectsR01AG015982 · NIA · NORTHWESTERN UNIVERSITY · PI SCHWARTZ, JANICE B · 1999 to 2009
$2.2M
Optimizing Clinical Trial Endpoints in Frontotemporal DementiaK23AG061253 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STAFFARONI, ADAM MARK · 2019 to 2023
$946k
Sensory Impairments, Cognitive Decline, and Dementia: What Explains the Association?K01AG062722 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BRENOWITZ, WILLA DOMINO · 2019 to 2023
$652k
Medical Research Council MC_PC_17228Medical Research Council MC_QA137853NIA NIH HHS K01 AG062722NIA NIH HHS K23 AG061253NIA NIH HHS R01 AG015982NIA NIH HHS R01 AG057869
6 · The paper itself

Abstract

Importance: Identifying the youngest age when Alzheimer disease (AD) influences cognition and the earliest affected cognitive domains will improve understanding of the natural history of AD and approaches to early diagnosis. Objective: To evaluate the age at which cognitive differences between individuals with higher compared with lower genetic risk of AD are first apparent and which cognitive assessments show the earliest difference. Design, Setting, and Participants: This cross-sectional study used data from UK Biobank participants of European genetic ancestry, aged 40 years or older, who contributed genotypic and cognitive test data from January 1, 2006, to December 31, 2015. Data analysis was performed from March 10, 2020, to January 4, 2022. Exposure: The AD genetic risk score (GRS), which is a weighted sum of 23 single-nucleotide variations. Main Outcomes and Measures: Seven cognitive tests were administered via touchscreen at in-person visits or online. Cognitive domains assessed included fluid intelligence, episodic memory, processing speed, executive functioning, and prospective memory. Multiple cognitive measures were derived from some tests, yielding 32 separate measures. Interactions between age and AD-GRS for each of the 32 cognitive measures were tested with linear regression using a Bonferroni-corrected P value threshold. For cognitive measures with significant evidence of age by AD-GRS interaction, the youngest age of interaction was assessed with new regression models, with nonlinear specification of age terms. Models with youngest age of interaction from 40 to 70 years, in 1-year increments, were compared, and the best-fitting model for each cognitive measure was chosen. Results across cognitive measures were compared to determine which cognitive indicators showed earliest AD-related change. Results: A total of 405 050 participants (mean [SD] age, 57.1 [7.9] years; 54.1% female) were included. Sample sizes differed across cognitive tests (from 12 455 to 404 682 participants). The AD-GRS significantly modified the association with age on 13 measures derived from the pairs matching (range in difference in mean cognition per decade increase in age for 1-SD higher AD-GRS, 2.5%-11.5%), symbol digit substitution (range in difference in mean cognition per decade increase in age for 1-SD higher AD-GRS, 2.0%-5.8%), and numeric memory tests (difference in mean cognition per decade increase in age for 1-SD higher AD-GRS, 8.8%) (P = 1.56 × 10-3). Best-fitting models suggested that cognitive scores of individuals with a high vs low AD-GRS began to diverge by 56 years of age for all 13 measures and by 47 years of age for 9 measures. Conclusions and Relevance: In this cross-sectional study, by early midlife, subtle differences in memory and attention were detectable among individuals with higher genetic risk of AD.

Indexed as

Alzheimer DiseaseCognition DisordersAdolescentAdultAgedCross-Sectional StudiesExecutive FunctionFemaleHumansMaleMiddle AgedNeuropsychological Tests

Identifiers

PMID35377426
PMCPMC8980909
OpenAlexW4224240251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.